氨磺必利与利培酮治疗首发精神分裂症疗效和安全性

Curative effect and safety of amisulpride with risperidone in the patients with first-episode schizophrenia

目的探讨首发精神分裂症患者采用氨磺必利与利培酮治疗的临床疗效和安全性。方法入选我院2014年12月至2016年12月期间收治的精神分裂症患者80例,所有患者根据药物治疗的不同分为利培酮组和氨磺必利组,其中40例给予利培酮治疗作为利培酮组,另40例给予氨磺必利治疗作为氨磺必利组;观察两组患者用药后的临床疗效和安全性。结果两组患者治疗后,临床症状均有所改善,氨磺必利组治疗总有效率87.5%略高于利培酮组85.0%,氨磺必利组用药后不良反应率27.5%略低于利培酮42.5%,差异无统计学意义(P>0.05);氨磺必利组患者阴性症状和CDSS减分幅度明显优于利培酮组,差异具有统计学意义(P<0.05)。结论氨磺必利与利培酮治疗首发精神分裂症的总体疗效相当,但氨磺必利改善患者阴性症状、情感症状方面效果显著,且不良反应少,对患者体重、泌乳素的影响较小。

Objective To study the clinical efficacy and safety of amisulpride and risperidon in the patients with first-episode schizophrenia. Methods During December 2014 to December 2016,80 patients with schizophrenia admitted in our hospital were randomly divided into two groups,40 patients were given risperidone as risperidone group, another 40 patients were given amisulpride as amisulpride group; The clinical efficacy and safety of the medicine in two groups were observed. Results Clinical symptoms after treatment were improved in two groups,the effective rate in the amisulpride group was 87.5%, which was slightly higher than 85.0% in risperidone group, drug adverse reaction rate in amisulpride group was 27.5%, which was slightly lower than 42.5% in risperidone group, the difference was no statistically significant（P 〉 0.05） ;The negative symptoms and CDSS points range in amisulpride group were obviously better than that of risperidone group,the difference was statistically signifieant（P〈~0. 05）. Conclusion The curative effect of amisulpride and risperidone in the treatment of first-episode schizophrenia are same,but the effect of amisulpride on the improvement of patients＇ negative symptoms and emotional symptoms is remarkable, and less adverse reaction,less effect on the patients＇ weight and prolactin.